Ordering Recommendation

Diagnostic or predictive test for MUTYH-associated polyposis. Use if one or no pathogenic variant is found with MUTYH-associated polyposis 2 mutations test.

Mnemonic
MUTYH FGS
Methodology

Polymerase Chain Reaction/Sequencing

Performed

Varies

Reported

14-21 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions
Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months

Reference Interval
Interpretive Data

Background Information for MUTYH-Associated Polyposis (MUTYH) Sequencing:
Characteristics of MUTYH-Associated Polyposis (MAP):
Development of colonic polyps (10-100) in the third decade or later.
Incidence:
Less than 1 percent of colorectal cancer cases.
Inheritance:
Autosomal recessive.
Penetrance:
Greater than 99 percent in untreated individuals. 
Cause:
Pathogenic biallelic MUTYH gene mutations.
Clinical Sensitivity:
98 percent of MUTYH mutations.
Methodology:
Bidirectional sequencing of the MUTYH coding regions and intron-exon boundaries.
Analytical Sensitivity and Specificity:
99 percent.
Limitations
: Diagnostic errors can occur due to rare sequence variations. Regulatory region MUTYH mutations, deep intronic mutations, and large deletion/duplications will not be detected. This assay is not designed to detect somatic variants associated with malignancy. Interpretation of this test result may be impacted if the patient has had an allogeneic stem cell transplantation.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
Hotline History
N/A
CPT Codes

81406

Components
Component Test Code* Component Chart Name LOINC
2004912 MUTYH-Associated Polyposis Specimen 31208-2
2006194 MUTYH-Assoc Polyposis Sequencing Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • MAP Sequencing
  • MYH-Associated Polyposis Sequencing
MUTYH-Associated Polyposis (MUTYH) Sequencing